Pharmaceuticals

Johnson & Johnson Acquires Investigational Numab Antibody for Atopic Dermatitis

bexib
By bexib 0 Min Read

The acquisition of the novel treatment for atopic dermatitis involves an all-cash transaction with total consideration of approximately $1.25 billion.

You Might Also Like

Great debut: Winrevair

Kiberna follows oncology CAR-T cell strategy for ultra-rare autoimmune disease

Resolution Presents Liver Disease Treatment Data at EASL 2024

Researchers combine herpes virus and cancer vaccine to treat childhood brain tumors

Merck Initiates Shorespan-007 Clinical Trial of Bomedemstat for Essential Thrombocythemia

Share This Article
Previous Article 2:00PM Water Cooler 5/28/2024 | naked capitalism
Next Article Make a Tortilla Press – Directions:
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Databricks expands into Indonesia, completes $10 billion funding round
Fintech
Real-Time Payments Surge in APAC as Modernisation Hurdles Persist
Fintech
How Antom helps merchants thrive in Southeast Asia and beyond
Fintech
Deal: Ally sells $2.3 billion credit card business to CardWorks
Banking